International Conference on Acute Lymphoblastic Leukaemia

17/05/2019@09:00_19/05/2019@18:00 Europe/Lisbon FusoHorário

International Conference on Acute Lymphoblastic Leukaemia

Berlin, Germany
May 17-19, 2019
Chairs: Jan Cools (Leuven), Hervé Dombret (Paris), Adele Fielding (London), Mark Litzow (Rochester)

Programme summary:
Major advances have been reached recently in the knowledge of acute lymphoblastic leukaemia (ALL), including the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, identi­ cation of new potentially druggable disease subsets and discovery of predisposing preleukemic events. During the same period of time, progresses have been accomplished in the management of children and adults with ALL, thanks to routine monitoring of measurable residual disease (MRD), administration of intensi­ ed risk-adapted chemotherapy, introduction of targeted therapies and antibodies, followed by the remarkable eff­icacy of antibody-drug conjugates (ADCs), bi speci­fic T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.

This intense research activity has made ALL a fascinating disease, allowing major improvements in patients’ outcome, while providing important proofs of concept for the treatment of cancer in general.

The 1st ESH Translational Conference on ALL is designed to provide time and multiple opportunities for discussions and interactions with internationally recognized physicians and scientists in the ­field.

Consulte aqui o programa provisório

Learning objectives:

  • Learn how to optimally diagnose and classify ALL, by combining modern diagnosis algorithms and early MRD monitoring, to rapidly deliver the right treatment to the right patient
  • Review the conventional therapeutic options, with a focus on the role of allogeneic haematopoietic stem cell transplantation
  • Learn how to optimize the management of individual patients on the basis of individual drug metabolism, tolerance and toxicity
  • Acquire improved knowledge of new emerging targeted or immunologic treatments and understand how they might be combined or even eventually replace current conventional treatment options


The programme will include:

  • Plenary Sessions
  • Introductory and Keynote Lectures
  • Roundtables
  • Panel Discussions
  • Simultaneous Meet the Expert Sessions
  • Manned Poster Session